progastrin releasing peptide Pro-gastrin - Pro GRP tumor marker releasing peptide Progastrin Releasing Peptide: A Crucial Biomarker in Disease Diagnosis

CYFRA 21-1 Progastrin releasing peptide (ProGRP), a significant precursor to the neuropeptide gastrin-releasing peptide (GRP), has emerged as a critical biomarker in the medical field, particularly in the diagnosis and monitoring of certain cancers. This peptide is synthesized as a larger precursor molecule and is subsequently cleaved to form the active releasing peptide. Understanding the role and significance of ProGRP is vital for healthcare professionals and researchers alike.Pro-gastrin-releasing peptide in patients with benign and ...

Understanding Progastrin Releasing Peptide

Pro-gastrin-releasing peptide is a protein that plays a role in various biological processes作者：NV Lyubimova·2022·被引用次数：8—Pro-Gastrin-Releasing Peptideas a Marker of Small Cell Lung Cancer ... The serum levels ofpro-gastrin-releasing peptide(proGRP), neuron- .... It is the precursor of gastrin-releasing peptide, a hormone that stimulates the secretion of gastrin, thereby increasing gastric acid acidity. ProGRP itself, however, has gained prominence primarily as a tumor marker. Its expression is notably elevated in certain types of neuroendocrine tissue differentiation, making it a valuable indicator in specific clinical contexts作者：NV Lyubimova·2022·被引用次数：8—Pro-Gastrin-Releasing Peptideas a Marker of Small Cell Lung Cancer ... The serum levels ofpro-gastrin-releasing peptide(proGRP), neuron- .... The Pro-gastrin molecule, as a precursor, holds key information about the production and potential pathology related to GRP.

ProGRP as a Biomarker for Small Cell Lung Cancer (SCLC)

The most well-established application of ProGRP is its use as a biomarker for small cell lung cancer (SCLC)Progastrin-releasing peptide(ProGRP) is a recently identified biomarker of small cell lung cancer (SCLC), a disorder of neuroendocrine tissue differentiation.. Numerous studies have demonstrated that serum ProGRP levels are significantly elevated in patients with SCLC. This makes ProGRP a sensitive and specific marker for this aggressive form of lung cancer, often outperforming other established tumor markers such as neuron-specific enolase (NSE).

Research has shown that ProGRP can be a more sensitive and specific biomarker of SCLC than NSEPro-gastrin-releasing peptide (ProGRP) as a biomarker in .... The ProGRP blood test is frequently utilized to aid in the diagnosis, treatment monitoring, and assessment of treatment response in SCLC patients.Manfaat: Pemeriksaan yang digunakan sebagai penanda tumor untuk diagnosis, pengobatan dan pemantauan pasien dengan kanker paru-paru sel kecil (SCLC). Persiapan ... For instance, studies have indicated that ProGRP results can correlate with tumor extension in SCLC, with higher sensitivity in extensive disease compared to limited disease. The ProGRP tumor marker is considered to be a sensitive tumor biomarker for SCLC.

Furthermore, ProGRP has also been investigated for its potential role in identifying well-differentiated neuroendocrine tumors (WDNETs), including bronchopulmonary carcinoids. An elevated ProGRP level can serve as a strong indication for a primary tumor in certain contexts, contributing to differential diagnosis.Pro-gastrin-releasing peptide(proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer ...

Beyond SCLC: ProGRP in Other Conditions

While SCLC is the primary focus, research suggests that ProGRP levels can be increased in a variety of benign and malignant diseases. This indicates that ProGRP might not be exclusively indicative of SCLC and can be influenced by other conditions.

For example, studies have compared serum ProGRP concentrations in patients with pneumonia, chronic obstructive pulmonary disease (COPD), and early-stage lung cancer.作者：LE Schonebaum·被引用次数：5—Abstract. Background: Calcitonin (CT), a well-established tumor marker for medullary thyroid carcinoma (MTC), is limited by a high rate of false ... Some findings suggest that concentrations of proGRP in pneumonia and COPD patients can be higher than in early stages of adenocarcinoma (ADC) and squamous cell carcinoma (SQCC)Pro-gastrin-releasing peptide in patients with benign and .... This highlights the importance of considering the clinical context when interpreting ProGRP levels.

Additionally, elevated ProGRP levels have been observed in other malignant conditions, prompting investigations into its broader diagnostic utility. The Pro-gastrin precursor's role in these varied disease states is an ongoing area of research.serum levels of Pro-Gastrin-releasing peptide precursor ...

Technical Aspects and Diagnostic Considerations

The measurement of ProGRP is typically performed through blood tests. The ProGRP normal range can vary slightly between laboratories, but generally, elevated levels are considered significant. For instance, median ProGRP concentrations in benign conditions, other malignancies, or non-small cell lung cancer (NSCLC) are reported to be lower compared to SCLC.Pro-Gastrin-Releasing Peptide(31-98) Is a Specific Tumor ...

The Pro-gastrin releasing peptide (31-98) fragment has been identified as a specific product of SCLC cellsProGRP: a new biomarker for small cell lung cancer - PubMed. Sophisticated assays, such as the Elecsys® platform, are being developed and evaluated for their accuracy in measuring plasma ProGRP. These advancements aim to improve the reliability and standardization of ProGRP testing作者：NV Lyubimova·2022·被引用次数：8—Pro-Gastrin-Releasing Peptideas a Marker of Small Cell Lung Cancer ... The serum levels ofpro-gastrin-releasing peptide(proGRP), neuron- ....

It is important to note that while Pro-gastrin-releasing peptide is a valuable biomarker, histopathology from biopsy or cytology remains the gold standard for definitive diagnosis of SCLC. However, ProGRP assays provide crucial supporting information for diagnosis, staging, and monitoring treatment efficacy. ProGRP and NSE levels are considered of paramount significance for the clinical diagnosis and staging of SCLC patientsPro-gastrin-releasing-peptide.

Future Directions

The continued research into ProGRP holds promise for expanding its diagnostic and therapeutic applications.作者：M Grønberg·2025·被引用次数：1—Progastrin-releasing peptide(ProGRP) is a more sensitive and specific biomarker of SCLC than neuron-specific enolase (NSE). We investigated ... Investigations are exploring its role not only as a diagnostic marker but also as a potential therapeutic target. The complex interplay of gastrin, peptide signaling, and releasing peptide mechanisms suggests that further understanding of ProGRP could lead to novel treatment strategies. The investigation into progastrin and its related peptide forms continues to be a vital area in medical research.